Health Care [ 9/12 ] | Biotechnology [ 47/73 ]
NYSE | Common Stock
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4.
The company was founded in 2018 and is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.13 Decreased by -91.43% | -0.12 Decreased by -11.67% |
| Feb 26, 25 | -0.12 Decreased by -94.17% | -0.12 Increased by +2.92% |
| Nov 4, 24 | -0.15 Decreased by -66.67% | -0.13 Decreased by -15.38% |
| Aug 5, 24 | -0.15 Decreased by -66.67% | -0.06 Decreased by -150.00% |
| May 14, 24 | -0.07 Increased by +30.00% | -0.10 Increased by +30.00% |
| Feb 29, 24 | -0.06 Increased by +40.00% | -0.10 Increased by +40.00% |
| Nov 2, 23 | -0.09 Increased by +25.00% | -0.11 Increased by +18.18% |
| Aug 3, 23 | -0.09 Increased by +43.75% | -0.11 Increased by +18.18% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 3.08 M Increased by +1.07 K% | -53.24 M Decreased by -259.90% | Decreased by -1.73 K% Increased by +69.19% |
| Dec 31, 24 | 5.71 M Increased by +2.06 K% | -49.45 M Decreased by -258.63% | Decreased by -865.79% Increased by +83.42% |
| Sep 30, 24 | 727.00 K Increased by +N/A% | -41.21 M Decreased by -109.73% | Decreased by -5.67 K% Decreased by N/A% |
| Jun 30, 24 | 1.44 M Increased by +N/A% | -462.49 M Decreased by -2.14 K% | Decreased by -32.23 K% Decreased by N/A% |
| Mar 31, 24 | 264.00 K Increased by +N/A% | -14.79 M Increased by +31.92% | Decreased by -5.60 K% Decreased by N/A% |
| Dec 31, 23 | 264.00 K Increased by +N/A% | -13.79 M Decreased by -85.18% | Decreased by -5.22 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Increased by +100.00% | -19.65 M Increased by +21.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Increased by +100.00% | -20.64 M Increased by +35.19% | Decreased by N/A% Decreased by N/A% |